타이틀

IR/PRNovel Small-Molecule ROCK2 Inhibitor GNS-3595 Attenuates Pulmonary Fibrosis in Preclinical Studies

IR/PRNovel Small Molecule ROCK Inhibitor GNS-3595 Attenuates Idiopathic Pulmonary Fibrosis Progression in Preclinical Models

IR/PRESMO ASIA 2022: A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation

IR/PRESMO 2020: Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

IR/PRLancet: Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label...

IR/PRClinical Cancer Research: YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer